Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucatinib with capecitabine and/or trastuzumab in HER2+ metastatic breast cancer
NCT02025192Phase 1Completed
- Sponsor
- Seagen Inc.
- Start
- Dec 2013
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tucatinib in HER2-positive metastatic breast cancer, sponsored by Seagen Inc. Started Dec 2013; status: completed.
02
Drugs
tucatinib
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT02025192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02025192.